Skip to main content

zavegepant

Generic: ZAVEGEPANT HYDROCHLORIDE·Brand: ZAVZPRET, Zavzpret

zavegepant: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

zavegepant evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect zavegepant to PFE; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could zavegepant → PFE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Migraine

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
PFIZER INC (PFE)Approved
PFIZER INC (PFE)Approved
Clinical Trials (1)

A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department

NCT07667621·Phase 1
Not yet recruiting

Primary endpoint: Pain relief at 2 hours without rescue medication

Interventionalopen100 targetStarted 2026-07Completion 2027-081 site · United StatesUniversity of South Florida
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ( 1 )(PFE)FDA ↗
NDA216386Type 1 - New Molecular EntityStandardOtherSpray, Metered

Frequently asked questions

Who is developing zavegepant?

zavegepant is being developed by PFIZER INC.

How many clinical trials involve zavegepant?

BioSniper tracks 1 clinical trial involving zavegepant.

What is zavegepant's latest FDA decision?

The most recent tracked FDA decision for zavegepant is Approval for 1 INDICATIONS AND USAGE ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ( 1 ), dated March 9, 2023.